drugset
drugset / Trial / NCT06098651

A Study of DCR-STAT3 in Adults With Solid Tumors

NCT06098651 ↗

Phase 1 Completed 26 enrolled Dicerna Pharmaceuticals, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.

Timeline

Start
2023-08-14
Primary completion
2025-09-17
Completion
2025-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject DCR-STAT3 Unknown — Intravenous

Indications

refractory malignant neoplasm